Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models

Anti-disialoganglioside GD2 antibody ch14.18/CHO (dinutuximab beta, DB) improved the outcome of patients with high-risk neuroblastoma (HR-NB) in the maintenance phase. We investigated chemotherapeutic compounds used in newly diagnosed patients in combination with DB. Vincristine, etoposide, carbopla...

Full description

Bibliographic Details
Main Authors: Sascha Troschke-Meurer, Maxi Zumpe, Lena Meißner, Nikolai Siebert, Piotr Grabarczyk, Hannes Forkel, Claudia Maletzki, Sander Bekeschus, Holger N. Lode
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Cancers
Subjects:
ADCC
carboplatin
chemoimmunotherapy
cisplatin
cyclophosphamide
dinutuximab beta
Online Access:https://www.mdpi.com/2072-6694/15/3/904

Internet

https://www.mdpi.com/2072-6694/15/3/904

Similar Items